Urantide acts as selective and competitive urotensin-II (UT) receptor antagonist (pKB = 8.3), which blocks hU-II induced contractions in thoracic aorta ex vivo, and has no effect on noradrenaline or endothelin 1-induced contraction or on acetylcholine-induced relaxation. It behaves as a partial agonist in a calcium mobilization assay (in CHO cells expressing hUT receptors).
CAT No: R1053
CAS No:669089-53-6
Synonyms/Alias:URANTIDE;669089-53-6;(2S)-2-[[(4R,7S,10S,13R,16S,19S)-19-[[(2S)-2-amino-3-carboxypropanoyl]amino]-10-(3-aminopropyl)-16-benzyl-7-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-20,20-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-methylbutanoic acid;(Pen5,DTrp7,Orn8)U-II (4-11) (human);[Pen5,DTrp7,Orn8]U-II (4-11) (human);CHEMBL223905;BDBM50411333;AKOS025147344;(Pen(5),DTrp(7),Orn(8))hU-II(4-11);
In vivo daily administration of urantide for three days resulted in reduced blood TG, TC, HDL and LDL levels in rat aortic tissue, in addition to the downregulation of the expression of the inflammatory mediators CRP and MCP-1, thus improving the symptoms of AS. These effects were identified to be time-dependent.
Urantide improves atherosclerosis by controlling C reactive protein, monocyte chemotactic protein 1 and transforming growth factor-β expression in rats
Urantide, a hU-II analogue, is a potent UT receptor antagonist that could block hU-II-induced contractions in the rat isolated thoracic aorta and displaces 125I-hU-II binding on UT receptor transfected CHO/K1 cells. Though our preliminary studies have shown that urantide had a protective effect against myocardial IR injury in rats and mice, the cardioprotection property needed to be confirmed by further study. The post-receptorial mechanism of urantide on myocardial IR injury is still not clear. It is currently known that protein kinase C (PKC) and phosphtidylinositol 3′-kinase – Akt (PI3K–Akt) signaling pathways are involved in protection against myocardial IR injury. The present study was therefore designed to confirm the protective effect of urantide against myocardial IR injury in rats and to investigate whether PKC and PI3K–Akt signaling pathways are involved in the protective effects of urantide.
Protective effect of urantide against ischemia–reperfusion injury via protein kinase C and phosphtidylinositol 3′-kinase – Akt pathway
1. High fat diet and GLP-1 drugs induce pancreatic injury in mice
5. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More